Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- If our product candidates do not receive regulatory approval, our business may be harmed.
- Manufacturing problems experienced by our third-party manufacturers could delay supply of clinical product candidates.
- Our accumulated deficit increased from $288 million to $313 million, indicating worsening financial health.
- We may not have sufficient resources to continue operations beyond the first quarter of fiscal 2024.
- Our failure to comply with NYSE American listing standards could result in delisting from the exchange.
- We cannot predict if reliance on reduced disclosure requirements will make our common stock less attractive.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1420720&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.